NeuroPace, Inc.

NasdaqGM NPCE

NeuroPace, Inc. Shareholders' Equity for the quarter ending September 30, 2024: USD 9.82 M

NeuroPace, Inc. Shareholders' Equity is USD 9.82 M for the quarter ending September 30, 2024, a -39.97% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

NeuroPace, Inc. Shareholders' Equity for the quarter ending September 30, 2023 was USD 16.36 M, a -62.31% change year over year.
NeuroPace, Inc. Shareholders' Equity for the quarter ending September 30, 2022 was USD 43.41 M, a -46.88% change year over year.
NeuroPace, Inc. Shareholders' Equity for the quarter ending September 30, 2021 was USD 81.71 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGM: NPCE

NeuroPace, Inc.

CEO	Mr. Joel D. Becker
IPO Date	April 22, 2021
Location	United States
Headquarters	455 North Bernardo Avenue
Employees	184
Sector	Health Care
Industries Pharmaceuticals Telehealth Virtual Reality (VR)

Description

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Key trends

Past 5 years